COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma

Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced BRAF V600–mutant melanoma. Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials.gov i...

Descripción completa

Detalles Bibliográficos
Autores principales: Dummer, Reinhard, Flaherty, Keith T., Robert, Caroline, Arance, Ana, de Groot, Jan Willem B., Garbe, Claus, Gogas, Helen J., Gutzmer, Ralf, Krajsová, Ivana, Liszkay, Gabriella, Loquai, Carmen, Mandalà, Mario, Schadendorf, Dirk, Yamazaki, Naoya, di Pietro, Alessandra, Cantey-Kiser, Jean, Edwards, Michelle, Ascierto, Paolo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916040/
https://www.ncbi.nlm.nih.gov/pubmed/35862871
http://dx.doi.org/10.1200/JCO.21.02659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916040/
https://www.ncbi.nlm.nih.gov/pubmed/35862871
http://dx.doi.org/10.1200/JCO.21.02659

Ejemplares similares